オハイオにおける卵巣上皮性癌の臨床試験
オハイオ内の拠点で、卵巣上皮性癌に関する10件の研究が参加者を募集しています。
オハイオ内の都市
公式研究テキスト（英語）
Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian Cancer
- Research Site, Cleveland
被験者募集中第3相
18歳以上 · 女性 · 2026/10/01更新 · NCT07851025A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
- Metrohealth Medical Center - Cleveland /ID# 276664, Cleveland
- Cleveland Clinic - Cleveland /ID# 276133, Cleveland
- Cleveland Clinic - Cleveland /ID# 278273, Cleveland
- 他3件
被験者募集中第2相
18歳以上 · 女性 · 2026/09/29更新 · NCT06890338Study of AVZO-021 in Patients With Advanced Solid Tumors
- Avenzo Therapeutics Recruiting Site, Cleveland
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/28更新 · NCT05867251ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- Cleveland Clinic, Cleveland
- Toledo Clinic Cancer Center, Toledo
被験者募集中観察研究
18歳以上 · 全性別 · 2026/09/14更新 · NCT05059444Fasting During Neoadjuvant Chemotherapy in Patient With Epithelial Ovarian Cancer
- Department of Subspecialty Care for Women's Health Women's Health; Division of Gynecologic Oncology, Case Comprehensive Cancer Center, Cleveland
被験者募集中
18歳以上 · 女性 · 2026/08/06更新 · NCT06386887AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
- Research Site, Blue Ash
- Research Site, Dayton
- Research Site, Sylvania
被験者募集中第3相
18歳以上 · 女性 · 2026/07/21更新 · NCT07218809Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
- Miami Valley Hospital South, Centerville
被験者募集中第3相
18歳以上 · 女性 · 2026/07/02更新 · NCT06819007A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
- Stefanie Spielman Comprehensive Breast Center, Columbus
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/03/27更新 · NCT06395519CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
- The James Cancer Hospital and Solove Research Institute - Ohio State University, Columbus
被験者募集中第2相
18歳以上 · 女性 · 2025/12/23更新 · NCT06690775Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
- Cleveland Clinic, Cleveland
被験者募集中第1相
18歳以上 · 全性別 · 2025/08/15更新 · NCT04429542ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。